Results 141 to 150 of about 76,984 (297)

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation

Alimentary Pharmacology &Therapeutics, EarlyView.
In liver transplant recipients with coexistent inflammatory bowel disease, incidence of infectious events observed between those exposed to ‘gut‐specific’ and ‘systemic’ biologics were similar. Biologic choice should not be influenced by concerns regarding their co‐prescription with transplant immunosuppression.
Simone Chin, Danny Con, Patrick Hilley, Crispin Corte, Ken Liu, Adam Testro, Peter De Cruz, Matthew C. Choy, Ashish Srinivasan   +8 more
wiley   +1 more source

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020

Alimentary Pharmacology &Therapeutics, EarlyView.
Colectomy rates in ulcerative colitis have declined over the last two decades, coinciding with increased use of advanced therapies. These trends reflect significant changes in treatment approaches and provide valuable data to support informed decision‐making by patients, clinicians, and healthcare providers.
J. Couch, K. Thomas, T. R. Card, D. J. Humes   +3 more
wiley   +1 more source

Anti-Fibrotic Effect of Tacrolimus on Preventing Adhesion after Achilles Tendon Surgery in a Murine Model. [PDF]

Iran J Med Sci
Nazari SE, Ghorbani E, Al-Asady AM, Sayyed-Hosseinian SH, Rahmani F, Vahedi E, Avan A, Askarnia-Faal MM, Naimi H, Khazaei M, Hassanian SM.   +10 more
europepmc   +1 more source

HYPOGAMMAGLOBULINEMIA IN HEART TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS, MYCOPHENOLATE, AND PREDNISONE

, 1999
Robin K. Avery, S D Mawhorter, Randall C. Starling, Patrick McCarthy, Nicholas Smedira, Marlene Goormastic, D. Pelegrin, Mark Majercik, Richard Hobbs, Katherine J. Hoercher, Dominique Cook, J B Young   +11 more
openalex   +1 more source

Immunosuppressive effect of tacrolimus (FK-506): Bone xenografts in rabbits [PDF]

, 1996
Shuji Ikebe, Shôgo Masumi, Hirokazu Yano, Tsutana Fukunaga, Kei Shimizu, Shuta Shin   +5 more
openalex   +1 more source

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono‐Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Hepatitis B immunoglobulins withdrawal in hepatitis B virus mono‐infected liver transplant recipients: An Italian multicentre prospective study. ABSTRACT Background & Aims Despite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside ...
Raffaella Viganò, Alessandro Loglio, Clara Dibenedetto, Paola Carrai, Silvia Martini, Ilaria Lenci, Bianca Magro, Sara Conti, Paolo Angelo Cortesi, Chiara Mazzarelli, Chiara Becchetti, Giovanni Perricone, Monica Cucco, Marco Carbone, Donatella Cocchis, Elisa Farina, Luisa Pasulo, Mauro Viganò, Michele Sagasta, Elisabetta Degasperi, Davide Ghinolfi, Pietro Lampertico, Stefano Fagiuoli, Luca Saverio Belli, on behalf of the INSIGHT‐B study group   +24 more
wiley   +1 more source

Ethnic differences in early blood tacrolimus concentrations after kidney transplantation: a retrospective observational study. [PDF]

BMC Nephrol
Thomas EC, Randall DW, Khurram MA, Yaqoob MM.   +3 more
europepmc   +1 more source

Absorption, Distribution and Excretion of 14C-labeled Tacrolimus(FK506) Ointment after a Single Dermal Application to the Rat.

, 1999
Kazuhide Iwasaki, Akio Kawamura, Yoshinori TERAMURA, Takehisa Hata, Shinichi Ninomiya, Yoshio ESUMI   +5 more
openalex   +2 more sources

Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy [PDF]

, 1996
Howard E. Corey, Vivian Tellis, Richard Schechner, Stuart Greenstein   +3 more
openalex   +1 more source

Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Features of clinically significant portal hypertension (CSPH) in patients with autoimmune hepatitis indicate a substantial risk for decompensation and impaired transplant‐free survival. Non‐invasive risk prediction based on liver stiffness measurement ≥ 15 kPa and/or thrombocytopenia (< 150 G/L) serves as a valuable surrogate to identify patients at ...
Lukas Burghart, Sonja Treiber, David Bauer, Emina Halilbasic, Benedikt S. Hofer, Mattias Mandorfer, Michael Gschwantler, Caroline Schwarz, Michael Trauner, Thomas Reiberger, Albert F. Stättermayer   +10 more
wiley   +1 more source